European Archives - Page 1184 of 1393 - European Medical Journal

Kidney Volume Evaluation in Autosomal Dominant Polycystic Kidney Disease Patients’ Renal Outcomes

Autosomal dominant polycystic kidney disease patients show end-stage renal disease progression, which requires suitable biomarkers to identify.

Neopterin, MCP-1, and MCSF as New Markers of Tubular Damage in Children with Chronic Kidney Disease on Conservative Treatment

Chronic kidney disease is characterised by enhanced migration of immunocompetent cells to the sites of inflammation, renal fibrosis, and irreversible…

Basal Forebrain Atrophy and Elevated Plasmatic Homocysteine Levels in Dementia Patients

Ondrej Lerch, MD from Charles University in Prague, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic discusses a study…

EuroPCR 2017 – Opening Ceremony

Our full congress review of EuroPCR 2017 is out now in our Interventional Cardiology 5.1 eJournal, and here we give you a look into the opening ceremony…

EMJ

ASSIST-FL – Primary Outcome: Interview with Prof. Jurczak

In this interview, Professor Wojciech Jurczak presents and discusses the primary results of ASSIST-FL, the confirmatory, PhIII randomised, double blinded…

RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease

Tel-Aviv, Israel / Raleigh, NC, USA, 12 July, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”)…

Abu Dhabi Health Show Comes to London

London, UK, 12 July, 2017 – Pri-Med Global is to re-brand its healthcare event into Future Healthcare UK, international exhibition and conference.

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer

Geneva, Switzerland, 12 July, 2017 – Genomic Health today announced that the 15th St. Gallen International Breast Cancer Conference Expert Panel endorsed…

What Is a Leader?

Leader. A word which we have become accustomed to in day-to-day life, but what does the word mean to you?

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

ASCO recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy